0001123292-21-000075.txt : 20210113 0001123292-21-000075.hdr.sgml : 20210113 20210113164457 ACCESSION NUMBER: 0001123292-21-000075 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210113 DATE AS OF CHANGE: 20210113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Liu Ye CENTRAL INDEX KEY: 0001840407 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 21526635 MAIL ADDRESS: STREET 1: ROOM 502-I, WANT WANT PLAZA STREET 2: NO. 211 SHIMEN YI ROAD CITY: SHANGHAI STATE: F4 ZIP: 200041 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2020-12-31 0 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001840407 Liu Ye ROOM 502-1, WANT WANT PLAZA NO. 211 YIMEN YI ROAD, JING'AN DISTRICT SHANGHAI F4 200041 CHINA 1 0 0 0 Common Stock, $0.001 par value 3010722 I Ocumension Therapeutics The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Exhibit 24: Power of Attorney /s/ Ron Honig, attorney-in-fact for Ye Liu 2021-01-13 EX-24 2 yliupoa.htm
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints the President and Chief Executive Officer, the Chief Financial Officer, and the Senior Vice President, General Counsel and Secretary of EyePoint Pharmaceuticals, Inc. (the “Company”), signing singly, and with full power of substitution, each as the undersigned’s true and lawful attorney-in-fact to:
(1)
execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or a director of the Company, the undersigned’s application for EDGAR Access with the United States Securities and Exchange Commission (Form ID application);
(2)
execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or a director of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(3)
do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to (A) complete and execute any such Forms 3, 4, or 5, (B) complete and execute any amendment or amendments thereto, and (C) timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
(4)
take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, and in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of January, 2021.

/s/ Ye Liu   
Signature    

Ye Liu        
Print Name